Katy Trinkley
Concepts (193)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Decision Support Systems, Clinical | 14 | 2025 | 279 | 5.740 |
Why?
| | Long QT Syndrome | 6 | 2025 | 68 | 2.880 |
Why?
| | Pharmacists | 7 | 2019 | 260 | 2.450 |
Why?
| | Electronic Health Records | 13 | 2025 | 1210 | 1.900 |
Why?
| | Primary Health Care | 10 | 2026 | 1776 | 1.750 |
Why?
| | Artificial Intelligence | 3 | 2026 | 389 | 1.360 |
Why?
| | Medical Order Entry Systems | 2 | 2021 | 40 | 1.200 |
Why?
| | Pharmacy Service, Hospital | 3 | 2019 | 90 | 1.180 |
Why?
| | Irritable Bowel Syndrome | 3 | 2015 | 28 | 1.170 |
Why?
| | Lisinopril | 2 | 2020 | 15 | 1.160 |
Why?
| | Heart Failure | 6 | 2023 | 2329 | 1.090 |
Why?
| | Practice Patterns, Physicians' | 6 | 2025 | 1408 | 1.040 |
Why?
| | Pharmacy Research | 1 | 2026 | 2 | 0.960 |
Why?
| | Hypertension | 4 | 2020 | 1272 | 0.940 |
Why?
| | Physicians | 3 | 2023 | 955 | 0.910 |
Why?
| | Medication Adherence | 4 | 2026 | 535 | 0.830 |
Why?
| | Constipation | 3 | 2015 | 98 | 0.770 |
Why?
| | Professional Role | 3 | 2019 | 172 | 0.710 |
Why?
| | Interprofessional Relations | 2 | 2015 | 275 | 0.700 |
Why?
| | Electrocardiography | 4 | 2024 | 667 | 0.660 |
Why?
| | Humans | 59 | 2026 | 146342 | 0.660 |
Why?
| | Losartan | 1 | 2020 | 13 | 0.650 |
Why?
| | Angioedema | 1 | 2020 | 16 | 0.640 |
Why?
| | Pharmaceutical Services | 2 | 2019 | 76 | 0.630 |
Why?
| | Text Messaging | 4 | 2026 | 188 | 0.610 |
Why?
| | Costs and Cost Analysis | 1 | 2020 | 217 | 0.590 |
Why?
| | Antipsychotic Agents | 2 | 2018 | 185 | 0.590 |
Why?
| | Pharmaceutical Preparations | 1 | 2021 | 172 | 0.580 |
Why?
| | Antihypertensive Agents | 2 | 2020 | 519 | 0.570 |
Why?
| | Analgesics, Opioid | 4 | 2025 | 1221 | 0.550 |
Why?
| | Pharmacies | 2 | 2019 | 40 | 0.510 |
Why?
| | Community Pharmacy Services | 1 | 2017 | 46 | 0.510 |
Why?
| | Dementia | 2 | 2018 | 324 | 0.490 |
Why?
| | Health Personnel | 2 | 2020 | 754 | 0.480 |
Why?
| | Chronic Pain | 2 | 2019 | 304 | 0.470 |
Why?
| | Program Development | 1 | 2018 | 371 | 0.470 |
Why?
| | Nursing Informatics | 1 | 2016 | 28 | 0.460 |
Why?
| | Reminder Systems | 3 | 2026 | 149 | 0.460 |
Why?
| | Depression | 4 | 2019 | 1575 | 0.450 |
Why?
| | Torsades de Pointes | 2 | 2024 | 23 | 0.440 |
Why?
| | Benzodiazepines | 1 | 2016 | 158 | 0.440 |
Why?
| | Students, Pharmacy | 1 | 2016 | 96 | 0.440 |
Why?
| | Referral and Consultation | 2 | 2019 | 881 | 0.430 |
Why?
| | Cyclohexanols | 1 | 2014 | 9 | 0.430 |
Why?
| | Aged | 17 | 2026 | 26432 | 0.420 |
Why?
| | Education, Pharmacy | 1 | 2016 | 125 | 0.420 |
Why?
| | Patient Transfer | 1 | 2017 | 224 | 0.420 |
Why?
| | Gastrointestinal Hemorrhage | 2 | 2025 | 134 | 0.410 |
Why?
| | Blood Pressure | 2 | 2020 | 1765 | 0.410 |
Why?
| | Fibromyalgia | 1 | 2014 | 52 | 0.410 |
Why?
| | Stroke Volume | 3 | 2023 | 652 | 0.400 |
Why?
| | Drug-Related Side Effects and Adverse Reactions | 1 | 2016 | 266 | 0.400 |
Why?
| | Naloxone | 2 | 2025 | 139 | 0.400 |
Why?
| | Nurse Practitioners | 1 | 2016 | 141 | 0.390 |
Why?
| | Pain Management | 1 | 2017 | 421 | 0.390 |
Why?
| | Patient Care Team | 2 | 2016 | 701 | 0.390 |
Why?
| | Computer-Assisted Instruction | 1 | 2014 | 69 | 0.390 |
Why?
| | Middle Aged | 19 | 2026 | 36619 | 0.390 |
Why?
| | Phentermine | 1 | 2013 | 14 | 0.380 |
Why?
| | Retrospective Studies | 11 | 2023 | 17438 | 0.380 |
Why?
| | Medical Informatics | 1 | 2014 | 102 | 0.370 |
Why?
| | Registries | 2 | 2020 | 2400 | 0.370 |
Why?
| | Narcotic Antagonists | 2 | 2025 | 210 | 0.370 |
Why?
| | Patient Safety | 1 | 2016 | 352 | 0.370 |
Why?
| | Fructose | 1 | 2013 | 132 | 0.360 |
Why?
| | Sleep Wake Disorders | 1 | 2016 | 314 | 0.360 |
Why?
| | Anti-Obesity Agents | 1 | 2013 | 67 | 0.360 |
Why?
| | Program Evaluation | 3 | 2025 | 952 | 0.350 |
Why?
| | Cooperative Behavior | 1 | 2015 | 471 | 0.350 |
Why?
| | Telemedicine | 3 | 2020 | 966 | 0.350 |
Why?
| | User-Computer Interface | 1 | 2013 | 168 | 0.350 |
Why?
| | Metformin | 1 | 2015 | 328 | 0.350 |
Why?
| | Anti-Inflammatory Agents, Non-Steroidal | 2 | 2025 | 344 | 0.340 |
Why?
| | Pharmacogenetics | 2 | 2024 | 176 | 0.320 |
Why?
| | Patient Discharge | 1 | 2017 | 997 | 0.320 |
Why?
| | Male | 24 | 2026 | 73396 | 0.310 |
Why?
| | Cardiovascular Diseases | 4 | 2026 | 2219 | 0.310 |
Why?
| | Female | 24 | 2026 | 79499 | 0.300 |
Why?
| | Internet | 1 | 2014 | 660 | 0.290 |
Why?
| | Anxiety | 1 | 2016 | 1125 | 0.280 |
Why?
| | Ambulatory Care | 3 | 2023 | 628 | 0.270 |
Why?
| | Focus Groups | 2 | 2023 | 588 | 0.270 |
Why?
| | Public Health | 1 | 2013 | 574 | 0.260 |
Why?
| | Health Knowledge, Attitudes, Practice | 1 | 2016 | 1408 | 0.250 |
Why?
| | Patient Participation | 3 | 2026 | 457 | 0.250 |
Why?
| | Cytochrome P-450 CYP2C19 | 2 | 2024 | 29 | 0.240 |
Why?
| | Serotonin and Noradrenaline Reuptake Inhibitors | 1 | 2025 | 6 | 0.230 |
Why?
| | Delivery of Health Care | 2 | 2024 | 947 | 0.230 |
Why?
| | Behavior | 2 | 2019 | 90 | 0.230 |
Why?
| | Antidepressive Agents | 3 | 2025 | 235 | 0.230 |
Why?
| | Cross-Sectional Studies | 4 | 2023 | 5899 | 0.230 |
Why?
| | Hypoglycemic Agents | 1 | 2015 | 1412 | 0.230 |
Why?
| | Reproducibility of Results | 3 | 2025 | 3416 | 0.230 |
Why?
| | Treatment Outcome | 6 | 2026 | 11821 | 0.210 |
Why?
| | Pain | 1 | 2010 | 790 | 0.210 |
Why?
| | Aged, 80 and over | 5 | 2026 | 8391 | 0.210 |
Why?
| | Risk Reduction Behavior | 1 | 2026 | 220 | 0.200 |
Why?
| | Inpatients | 2 | 2025 | 540 | 0.200 |
Why?
| | Risk Factors | 6 | 2025 | 10921 | 0.200 |
Why?
| | Disease Management | 2 | 2020 | 651 | 0.190 |
Why?
| | Adult | 12 | 2026 | 41087 | 0.190 |
Why?
| | Cardiovascular Agents | 1 | 2025 | 165 | 0.190 |
Why?
| | Prescriptions | 1 | 2023 | 77 | 0.190 |
Why?
| | Machine Learning | 2 | 2026 | 594 | 0.190 |
Why?
| | Multifactorial Inheritance | 1 | 2024 | 243 | 0.180 |
Why?
| | Dose-Response Relationship, Drug | 2 | 2020 | 2022 | 0.180 |
Why?
| | Triage | 1 | 2024 | 243 | 0.170 |
Why?
| | Evidence-Based Practice | 1 | 2024 | 231 | 0.170 |
Why?
| | Academic Medical Centers | 2 | 2026 | 561 | 0.170 |
Why?
| | Surveys and Questionnaires | 4 | 2025 | 6073 | 0.170 |
Why?
| | Behavioral Symptoms | 2 | 2018 | 43 | 0.160 |
Why?
| | Psychometrics | 1 | 2025 | 712 | 0.160 |
Why?
| | Diabetes Mellitus, Type 2 | 1 | 2015 | 2623 | 0.160 |
Why?
| | Physical Therapy Modalities | 1 | 2024 | 341 | 0.160 |
Why?
| | Anticoagulants | 1 | 2026 | 746 | 0.160 |
Why?
| | Chronic Disease | 3 | 2026 | 1827 | 0.160 |
Why?
| | Evaluation Studies as Topic | 1 | 2020 | 161 | 0.160 |
Why?
| | Platelet Aggregation Inhibitors | 1 | 2024 | 499 | 0.150 |
Why?
| | Health Behavior | 1 | 2026 | 802 | 0.150 |
Why?
| | Mental Health Services | 1 | 2025 | 450 | 0.150 |
Why?
| | Obesity | 1 | 2013 | 3131 | 0.150 |
Why?
| | Prospective Studies | 3 | 2016 | 8123 | 0.140 |
Why?
| | Grounded Theory | 1 | 2019 | 47 | 0.140 |
Why?
| | United States | 5 | 2026 | 16136 | 0.140 |
Why?
| | Biological Specimen Banks | 1 | 2020 | 137 | 0.140 |
Why?
| | Drug Administration Schedule | 1 | 2020 | 790 | 0.140 |
Why?
| | Evidence-Based Medicine | 2 | 2014 | 731 | 0.140 |
Why?
| | Sex Factors | 2 | 2015 | 2107 | 0.140 |
Why?
| | Medication Therapy Management | 1 | 2019 | 73 | 0.140 |
Why?
| | Residential Facilities | 1 | 2017 | 8 | 0.130 |
Why?
| | Curriculum | 2 | 2016 | 1079 | 0.130 |
Why?
| | Models, Organizational | 1 | 2018 | 145 | 0.130 |
Why?
| | Medication Errors | 1 | 2017 | 86 | 0.120 |
Why?
| | Independent Living | 1 | 2018 | 114 | 0.120 |
Why?
| | Telenursing | 1 | 2016 | 10 | 0.120 |
Why?
| | Intersectoral Collaboration | 1 | 2016 | 64 | 0.120 |
Why?
| | Angiotensin-Converting Enzyme Inhibitors | 1 | 2017 | 228 | 0.110 |
Why?
| | Health Care Surveys | 1 | 2017 | 541 | 0.110 |
Why?
| | Laxatives | 1 | 2015 | 22 | 0.110 |
Why?
| | Young Adult | 4 | 2026 | 14330 | 0.110 |
Why?
| | Precision Medicine | 1 | 2020 | 462 | 0.110 |
Why?
| | Office Visits | 1 | 2015 | 93 | 0.110 |
Why?
| | Venlafaxine Hydrochloride | 1 | 2014 | 12 | 0.110 |
Why?
| | Perception | 1 | 2017 | 373 | 0.110 |
Why?
| | Drugs, Investigational | 1 | 2014 | 31 | 0.100 |
Why?
| | Quality Improvement | 2 | 2020 | 1354 | 0.100 |
Why?
| | Systems Integration | 1 | 2014 | 36 | 0.100 |
Why?
| | PubMed | 1 | 2013 | 15 | 0.100 |
Why?
| | Randomized Controlled Trials as Topic | 3 | 2026 | 1763 | 0.100 |
Why?
| | Models, Educational | 1 | 2014 | 91 | 0.100 |
Why?
| | Adolescent | 4 | 2026 | 22557 | 0.090 |
Why?
| | Interviews as Topic | 1 | 2016 | 930 | 0.090 |
Why?
| | Emergency Service, Hospital | 1 | 2024 | 2363 | 0.090 |
Why?
| | Drug Combinations | 1 | 2013 | 400 | 0.090 |
Why?
| | Teaching | 1 | 2014 | 244 | 0.080 |
Why?
| | Follow-Up Studies | 1 | 2020 | 5439 | 0.080 |
Why?
| | Communication | 1 | 2017 | 980 | 0.080 |
Why?
| | Parasympatholytics | 1 | 2010 | 11 | 0.080 |
Why?
| | Antidiarrheals | 1 | 2010 | 12 | 0.080 |
Why?
| | Controlled Clinical Trials as Topic | 1 | 2010 | 26 | 0.080 |
Why?
| | Dietary Fiber | 1 | 2010 | 59 | 0.080 |
Why?
| | Life Style | 1 | 2013 | 496 | 0.080 |
Why?
| | Diarrhea | 1 | 2010 | 190 | 0.070 |
Why?
| | Abdominal Pain | 1 | 2010 | 149 | 0.070 |
Why?
| | Attitude of Health Personnel | 1 | 2017 | 1219 | 0.070 |
Why?
| | Cohort Studies | 1 | 2019 | 6077 | 0.070 |
Why?
| | Colorado | 2 | 2020 | 4595 | 0.070 |
Why?
| | Age Factors | 1 | 2015 | 3347 | 0.070 |
Why?
| | Clinical Competence | 1 | 2016 | 1272 | 0.060 |
Why?
| | Case-Control Studies | 2 | 2025 | 3647 | 0.060 |
Why?
| | Dietary Supplements | 1 | 2010 | 587 | 0.060 |
Why?
| | Risk Assessment | 2 | 2025 | 3712 | 0.060 |
Why?
| | Drug Overdose | 1 | 2010 | 377 | 0.060 |
Why?
| | Pragmatic Clinical Trials as Topic | 1 | 2026 | 135 | 0.060 |
Why?
| | Drug Interactions | 1 | 2026 | 405 | 0.050 |
Why?
| | Phenethylamines | 1 | 2024 | 16 | 0.050 |
Why?
| | Multicenter Studies as Topic | 1 | 2026 | 417 | 0.050 |
Why?
| | Cost-Benefit Analysis | 1 | 2026 | 640 | 0.050 |
Why?
| | Tertiary Care Centers | 1 | 2024 | 196 | 0.050 |
Why?
| | Drug Prescriptions | 1 | 2025 | 314 | 0.050 |
Why?
| | Motivation | 1 | 2026 | 605 | 0.040 |
Why?
| | Cluster Analysis | 1 | 2022 | 496 | 0.040 |
Why?
| | Hemorrhage | 1 | 2026 | 825 | 0.040 |
Why?
| | Health Services Misuse | 1 | 2020 | 33 | 0.040 |
Why?
| | Sulfonamides | 1 | 2024 | 594 | 0.040 |
Why?
| | Research Design | 1 | 2026 | 1143 | 0.040 |
Why?
| | Genotype | 1 | 2024 | 1879 | 0.040 |
Why?
| | Qualitative Research | 1 | 2026 | 1734 | 0.030 |
Why?
| | Quality of Life | 1 | 2010 | 3200 | 0.030 |
Why?
| | Ventricular Dysfunction, Left | 1 | 2020 | 391 | 0.030 |
Why?
| | Long-Term Care | 1 | 2017 | 118 | 0.030 |
Why?
| | Child | 1 | 2016 | 22693 | 0.030 |
Why?
| | Physician-Patient Relations | 1 | 2020 | 597 | 0.030 |
Why?
|
|
Trinkley's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|